AZD1656 (a specific glucokinase activator) had shown short-term efficacy in reducing blood glucose levels in people with type 2 diabetes and reduced the risk of skin transplant rejection in AZD1656-fed rodents, but its immune effects in humans and potential to treat COVID-19 humans was unknown. The gene discussed is GCK; the disease is COVID-19.